Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, sale, and marketing of branded prescription pharmaceutical products in women’s healthcare and dermatology primarily in the United States. It markets various products, including Loestrin 24 Fe, Ovcon 35 and Ovcon 50, and Estrostep for hormonal contraception; femhrt 1/5 and .5/2.5, and Estrace cream for hormone therapy; Taclonex and Dovonex for psoriasis; and Doryx for acne. The company’s product pipeline primarily includes WC2061, which is in a phase II pilot study for an extended use oral contraceptive; GD1105, a contraceptive vaginal ring that is in the preclinical phase; TD1414, a topical antibiotic for skin infections that is in late preclinical phase; and Taclonex Line Extension—LEO 80-185, a topical treatment for psoriasis of the scalp and body, and is in phase III clinical trials. Its principal customers include wholesale pharmaceutical distributors, and major retail drug and grocery store chains. The company was incorporated in 1968 and is headquartered in Rockaway, New Jersey.